Kordek R.: Onkologia. Podręcznik dla studentów i lekarzy, Wyd. 2, Gdańsk: Via Medica, 2006, 320-322.
Krajowy Rejestr Nowotworów, Zakład Epidemiologii i Prewencji Nowotworów Centrum Onkologii, wzięto z http://onkologia.org.pl/ z dnia 25.03.2020.
Stachura J., Domagała W.: Patologia: znaczy słowo o chorobie. Tom 1, Patologia ogólna, Kraków, PAU, 2008, 35-40.
Mitrus I., Szala S.: Chemioterapia – główne przyczyny niepowodzeń, Nowotwory, Journal of Oncology, 2009, 368-375.
Kuszyk B., Corl F., Franano F.: Tumor transport physiology: implications for imaging and imaging-guided therapy, Am J Roentgenol, 2001, 177(4): 747-753.
DOI: https://doi.org/10.2214/ajr.177.4.1770747
Cairns R., Papandreou I., Denko N.: Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment, Molecular Cancer Research, 2006, 4(2): 61-70.
DOI: https://doi.org/10.1158/1541-7786.MCR-06-0002
Minchinton A.I., Tannock I.F.: Drug penetration in solid tumours, Nature Reviews Cancer, 2006, 6(8): 583-592.
DOI: https://doi.org/10.1038/nrc1893
Blagosklonny M.V.: Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance, Cell Cycle, 2005, 4(2): 1693-1698.
DOI: https://doi.org/10.4161/cc.4.12.2259
Huff C.A., Matsui W., Smith B.D.: The paradox of response and survival in cancer therapeutics. Blood, 2006, 107(2): 431-434.
DOI: https://doi.org/10.1182/blood-2005-06-2517
Janik P.: Stemowe komórki nowotworowe, Nowotwory. Journal of Oncology, 2008, 58(3): 221-224.
Grzelakowska-Sztabert B.: Post Biochem, Folia Morphology, 1989, 35(2): 513-541.
Wang L.G., Liu X.M., Kreis W., Budman D.: Cancer Chemotherapy, Pharmacol, 1999, 44(2): 355-361.
DOI: https://doi.org/10.1007/s002800050989
Krishan A.: Med Cell Science, Journal of Cell Science, 2002, 24(2): 55-60.
DOI: https://doi.org/10.1023/A:1015513705359
Orzechowska-Juzwenko K.: Zarys chemioterapii nowotworów narządowych i układowych, Volumed, Wrocław, 2000, 13-73.
Nowak R., Tarasiuk J.: Hamowanie procesu apoptozy w komórkach nowotworowych opornych na działanie leków przeciwnowotworowych, 2004, 4(4): 330-343.
Li T.K,, Liu L.F. Toxicol,, Annual Reviev of Pharmacology, 2001, 41(2): 53-77.
DOI: https://doi.org/10.1146/annurev.pharmtox.41.1.53
Bozko P., Larsen K., Raymond E., Skladanowski A.: Influence of G arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status, Acta Biochimica Polonica, 2002, 49(1): 109-119.
DOI: https://doi.org/10.18388/abp.2002_3827
Krawczyk P., Kucharczyk T., Limon J., Dziadziuszko R., Milanowski J., Jassem J.: Prawne i metodologiczne aspekty genetycznych testów diagnostycznych w kwalifikacji chorych na nowotwory do terapii ukierunkowanych molekularnie, Journal of Oncology, 2013, 63(1): 1-7.
Pruszyński M.: Projektowanie, otrzymywanie i charakterystyka nowych radiofarmaceutyków molekularnych do diagnostyki i terapii nowotworów z nadekspresją receptora HER2, Instytut Chemii i Techniki Jądrowej, 2018.
Wysocki P.: Mechanizmy działania przeciwciał monoklonalnych w nowotworach litych, Onkologia w Praktyce Klinicznej, 2014, 10: 175- 183.
Krawczyk P., Wojas-Krawczyk K.: Przeciwciała monoklonalne przeciw immunologicznym punktom kontroli w leczeniu chorych na nowotwory, Onkologia w Praktyce Klinicznej, 2015,11(2): 76-86.
Postow M.A., Callahan M.K., Wolchok J.D.: Immune checkpoint blockade in cancer therapy. J. Clinical Oncology 2015; 20: 4358.
DOI: https://doi.org/10.1200/JCO.2014.59.4358
Gurgul A., Lityńska A.: Substancje pochodzenia roślinnego w terapii nowotworów, Post Fitoter 2017, 18(1): 203-208.
DOI: https://doi.org/10.25121/PF.2017.18.3.203
Rowinsky E.K., Cazenave L.A., Donehower R.: Taxol: a novel investigation alantimicrotubule agent, Journal of the National Cancer Institute, 1990, 82(15): 1247-59.
DOI: https://doi.org/10.1093/jnci/82.15.1247
Bodnar L., Wcisło G., Miedzińska-Maciejewska M., Szczylik C.: Docetaksel i paklitaksel: porównanie ich budowy, farmakologii oraz mechanizmów oporności, Postepy Higieny i Medycyny Doświadczalnej, 2010, 64(2): 568-581.
O’Brien M.E.R., Leonard R.C., Barrett-Lee P.J.: Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK., Oncology 1999, 10(6): 205-210.
DOI: https://doi.org/10.1023/A:1008370930599
Huisman C., Smit E.F., Giaccone G, Postmus P.E.: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer, Journal of Clinical Oncology, 2000, 18(4): 3722-3730.
DOI: https://doi.org/10.1200/JCO.2000.18.21.3722
Forastiere A., Shank D., Neuberg D.: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck, Cancer 1998, 82(1): 22-70.
DOI: https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q
Conteau C., Chouaki N., Leyvraz S.: Phase II study of docetaxel in patients with metastatic squamous cellcarcinoma of the head and neck, British Journal of Cancer,1999, 81(1): 457-462.
DOI: https://doi.org/10.1038/sj.bjc.6690715
Charakterystyka produktu leczniczego Paclitaxel, styczeń, 2017.
Khazir J., Mir B.A., Pilcher L.: Role of plants in anticancer drug discovery, Phytochemistry Letters, 2014, 7(4):173-181.
DOI: https://doi.org/10.1016/j.phytol.2013.11.010
Kampan N., Madondo M., McNally O.: Paclitaxel and its evolving role in the management of ovarian cancer, Biomed Research International, 2015,1-21.
DOI: https://doi.org/10.1155/2015/413076
Kingston D., Mangri N., Jintrangsri C.: Synthesis and structureactivity relationships of taxol derivatives as anti-cancer agents, New Trends in Natural Products Chemistry, 1986, 26(1): 219-234.
Lowe J., Li H. Downing, K. Nogales J.: Refined structure of alpha;beta;-tubulin at 3.5 p resolution, Journal of Molecular Biology, 2001, 31(3): 1045-1057.
DOI: https://doi.org/10.1006/jmbi.2001.5077
Bharadwaj K., Rajnish D., Yu H., Hongtao R.: The spindle checkpoint, aneuploidy and cancer, Oncogene, 2004, 23(12): 2016-2027.
DOI: https://doi.org/10.1038/sj.onc.1207374
Brito D. A., Yang, Z., Rieder, C. L.: Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied, The Journal of Cell Biology, 2004, 182(4): 623-629.
DOI: https://doi.org/10.1083/jcb.200805072
Weaver B.A.: How taxol/paclitaxel kills cancer cells, Molecular Biology of the Cell, 2014; 25(6): 2677-8.
DOI: https://doi.org/10.1091/mbc.e14-04-0916
Szoka Ł.: Metody biotechnologiczne w otrzymywaniu taksolu – cytostatycznego diterpenu cisów (Taxus), Gazeta Farmaceutyczna, 2009, 18(9):34-36.
Goodman J., Walsh V.: The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug, Cambridge University, 2001,179-182.
Stierle A., Strobel G., Stierle D.: Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of pacific yew. Science, 1993, 260(11): 214-216.
DOI: https://doi.org/10.1126/science.8097061
Linyan Z., Chen L.: Progress in research on paclitaxel and tumor immunotherapy, Cellular and Molecular Biology Letters, 2019, 24-40.
Liu K., Ding X., Deng B., Chen W.: Isolation and characterization of endophytic taxol-producing fungi from Taxus chinensis, Journal of Industral Microbiology and Biotechnology, 2009, 36(5): 1171-1177.
DOI: https://doi.org/10.1007/s10295-009-0598-8
Heinig U., Scholz S., Jennewein S.: Getting to the bottom of Taxol biosynthesis by fungi, Fungal Divers, 2013, 60(1): 161-170.
DOI: https://doi.org/10.1007/s13225-013-0228-7
Kusari S., Singh S., Jayabaskaran C.: Rethinking production of Taxol; (paclitaxel) using endophyte biotechnology, Trends Biotechnol, 2014, 32(7): 304-311.
DOI: https://doi.org/10.1016/j.tibtech.2014.03.011
Zhou X.W., Zhu H.F., Liu L., Lin J., Tang K.X.: A review: recent advances and future prospects of taxol-producing endophytic fungi, Applied Microbiology and Biotechnology, 2010, 86(3): 1707-1017.
DOI: https://doi.org/10.1007/s00253-010-2546-y
Yang Y., Mao J., Tan X.: Research progress on the source, production, and anti-cancer mechanisms of paclitaxel, Chinese Journal of Natural Medicines, 2020, 18(12): 890-897.
DOI: https://doi.org/10.1016/S1875-5364(20)60032-2
Rowinsky E.K., Wright M., Montsarrat B., Done-Hower R.C.: Clinical pharmacology and metabolism of Taxol (paclitaxel), Annals of Oncology, 1994, 5(1): 7-16.
Charakterystyka produktu leczniczego Paclitaxel Kabi, Fresenius Kabi Polska Sp. z.o.o., styczeń, 2020.
Charakterystyka produktu leczniczego Paclitaxelum Accord Accord Healthcare Polska Sp. z o.o., listopad, 2012.
Charakterystyka produktu leczniczego Paclimedac medac Gesellschaft für klinische Spezialpräparate mbH, lipiec, 2015.
Charakterystyka produktu leczniczego Paclitaxel-Ebewe Ebewe Pharma Ges.m.b.H Nfg. KG, listopad, 2019.
Adrianzen D. Herrera, Ashai N., Perez-Soler R., Cheng H.: Nanoparticle albumin bound paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence, Expert Opinion on Pharmacotherapy, 2019, 1: 95-102.
DOI: https://doi.org/10.1080/14656566.2018.1546290
Torre L.A., Siegel R.L., Jemal A.: Lung cancer statistics, Advances in Experimental Medicine and Biology, 2016, 893(1): 1-19.
DOI: https://doi.org/10.1007/978-3-319-24223-1_1
Gelderblom H., Verweij J., Nooter K.: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, European Journal of Cancer, 2001, 37(1): 1590-1598.
DOI: https://doi.org/10.1016/S0959-8049(01)00171-X
Socinski M.A., Bondarenko I., Karaseva N.: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced nonsmall-cell lung cancer: final results of a phase III trial, Journal of Clinical Oncology, 2012, 30(1): 2055-2062.
DOI: https://doi.org/10.1200/JCO.2011.39.5848
Ibrahim N.K., Desai N., Legha S.: Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel, Clinical Cancer Research, 2002, 5(3): 1038-1044.
Szebeni J. , Alving C.R., Savay S.: Formation of complementactivating particles in aqueous solutions of Taxol: possible role in
hypersensitivity reactions, Internationa Immunopharmacolpgy, 2001, 4(2): 721-735.
Gardner E.R., Dahut W.L., Scripture C.D.: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nabpaclitaxel, Clinical Cancer Research, 2008, 14(2): 4200–4205.
DOI: https://doi.org/10.1158/1078-0432.CCR-07-4592
Tiruppathi C., Song W., Bergenfeldt M.: Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinasedependent pathway, Journal of Biological Chemistry, 1997, 272(2): 259-265.
DOI: https://doi.org/10.1074/jbc.272.41.25968
Prakash V., Vivek R.: Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer, Breast Cancer: Basic and Clinical Research, 2011:5 53-65.
DOI: https://doi.org/10.4137/BCBCR.S5857
Tala M., Samaan A., Samec M., Liskova A., Kubatka P., Büsselberg D.: Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer, Biomolecules, 2019, 9(2): 788-789.
DOI: https://doi.org/10.3390/biom9120789
Ferlay K., Colombet J., Soerjomataram M., Mathers J., Parkin C., Piñeros D., Znaor M., Bray A.: Estimating the global cancer incidence
and mortality, Globocan, sources and methods, International Journal of Cancer, 2019, 144(4): 1941-1953.
DOI: https://doi.org/10.1002/ijc.31937
McPherson K., Steel C., Dixon M.: Breast cancer—Epidemiology, risk factors and genetics, British Medical Journal, 2000, 321(2): 624-628.
DOI: https://doi.org/10.1136/bmj.321.7261.624
Amin B.A., Edge S.B.: Cancer staging manual, Springer, New York, 2017, 93-99.
DOI: https://doi.org/10.3322/caac.21388
Jassem J., Krzakowski M., Bobek-Billewicz B., Duchnowska R., Jeziorski A., Olszewski W., Senkus-Konefka E., Tchórzewska-Korba H., Wysocki P.: Rak piersi, Onkologia w Praktyce Klinicznej, 2015, 11(3): 24-52.
Yu, D. Jing, T. Liu, B. Yao, J. Tan, M. McDonnell, T.J. Hung, M.: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase, Molecular Cell, 1998, 2(3): 581-591.
DOI: https://doi.org/10.1016/S1097-2765(00)80157-4
Hayes D.F. Thor, A.D., Dressler L.G., Weaver D., Edgerton S., Cowan D., Broadwater, G. Goldstein, L.J. Martino, S. Ingle, J.: HER2 and response to paclitaxel in node-positive breast cancer, The New England Journal of Medicine, 2007, 357(2): 1496-1506.
DOI: https://doi.org/10.1056/NEJMoa071167
Pogoda K., Krzakowski M., Jagiełło-Gruszfeld A.: Metronomic chemotherapy in breast cancer. Oncology in Clinical Practice, 2017;13:161-168.
Cancello G, Bagnardi V, Sangalli C:Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer, Clinical Breast Cancer, 2015, 15(4): 259-265
DOI: https://doi.org/10.1016/j.clbc.2015.03.002
Green M.R., Manikhas G.M., Orlov S.: Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer, Annal of Oncology, 2006, 8(11): 1263-1268.
DOI: https://doi.org/10.1093/annonc/mdl104
Rizvi N.A., Riely G.J., Azzoli C.G.: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer, Journal of Clinical Oncology, 2008, 26(1): 639-643.
DOI: https://doi.org/10.1200/JCO.2007.10.8605
Urbański K.: Terapia konsolidacyjna chorych na raka jajnika. Argumenty za i przeciw, Onkologia w Praktyce Klinicznej, 2007 Tom 3, nr 6, 298-305.
Jiying Y., Zengjuan J., Shufang D.: Cisplatin and paclitaxel codelivered by folatedecorated lipid carriers for the treatment of head and neck cancer, Drug Delivery, 2017, 24(1): 792-799.
DOI: https://doi.org/10.1080/10717544.2016.1236849
Roszkiewicz J., Nedoszytko B., Lange M.: Mięsak Kaposiego — fascynująca historia współczesnej medycyny, Forum Medycyny Rodzinnej 2010, 4(4): 246-254.
Kim S., Kim D., Lee H., Young J., Lee J., M.D.: Treatment of Disseminated Classic Type of Kaposi’s Sarcoma with Paclitaxel, Annals of Dermatology, 2011, 23(4):504-7.
DOI: https://doi.org/10.5021/ad.2011.23.4.504
Bower M., Palfreeman A., Alfa-Wali M., Bunker C.: British HIV Association guidelines for HIV-associated malignancies, HIV Medicine, 2014, 15(2): 1-92.
DOI: https://doi.org/10.1111/hiv.12136
Zhu L., Chen L.: Progress in research on paclitaxel and tumor immunotherapy, Cellular and Molecular Biology Letters, 2019, 12: 24-40.
DOI: https://doi.org/10.1186/s11658-019-0164-y
Mackiewicz J., Mackiewicz A.: Immunoterapia nowotworów i perspektywy jej rozwoju, Współczesna Onkologia, 2010, 14(2): 59-71.
DOI: https://doi.org/10.5114/wo.2010.13914
Vassileva V., Allen C.J., Piquette-Miller M.: Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer, Molecular Cancer Therapy, 2008, 7(3): 630-637.
DOI: https://doi.org/10.1158/1535-7163.MCT-07-2117
Lesterhuis W.J., Cornelis J.A.P., Hato S.V., Dagmar E.T., Bastiaan J.H.J., Stefan N.: Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice, Journal of Clinical Investigation, 2011, 12(1): 8-31
Spigel D.R., Patel J.D., Reynolds C.H., Garon E..B, Hermann R.C., Govindan R.: Quality of life analyses from the randomized, openlabel, phase III PointBreak study of pemetrexed-carboplatinbevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin -bevacizumab followed by maintenance bevacizumab in patients, Journal of Thoracic Oncology, 2015, 10(4): 353-359.
DOI: https://doi.org/10.1097/JTO.0000000000000277
Nagańska E.: Powikłania neurologiczne po leczeniu onkologicznym, Przewodnik Lekarza 2010, 9: 54-59.
Drat-Gzubicka J.: Schorzenia nerwowo-mięśniowe u pacjentów z chorobą nowotworową, Medycyna Paliatywna w Praktyce, 2015, 9(1): 8-15.
English
Język Polski
